Haemonetics, a medtech company, is expanding its recurring revenue through plasma consumables and higher-margin cardiovascular technologies. The company has shifted focus by divesting slower-growth operations and acquiring new businesses like Cardiva and OpSens. A recent agreement with CSL could further boost growth potential. Despite a strong rally in 2026, Haemonetics' valuation remains reasonable, making it a speculative buy for long-term investors.
Reddit joined the S&P 500 index on August 18, 2026, replacing AvalonBay Communities, which may increase demand for its shares from index-tracking funds. Morgan Stanley maintained an Overweight rating on Reddit but lowered its price target from $240 t...
BJ's Wholesale Club reported quarterly earnings per share of $1.36 and revenue of $6.23 billion, surpassing analyst expectations. The growth was driven by budget-conscious shoppers and strong membership momentum, pushing sales beyond the company's fo...
UBS analyst Radi Sultan set a $40 price target for GitLab Inc., suggesting a nearly 5% downside from its current $42.08 share price. Despite this cautious outlook, the rise of AI is boosting demand for GitLab's software development platform, especial...
DraftKings (DKNG) shares closed at $25.03 on August 20, 2026, well below their 52-week high of $48.78, reflecting significant volatility. Wall Street analysts mostly maintain a positive outlook, with many recommending Buy or Strong Buy and average pr...
Equifax received an analyst upgrade to 'Buy' with a new price target of $235, indicating a potential 22% gain from its current price. The company reported strong Q2 2026 earnings and revenue that exceeded expectations, driving a 12.7% stock rise. Des...
